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Abstract
Background: Sporadic colorectal cancers (CRC) are multifactorial diseases resulting from the
combined effects of numerous genetic, environmental and behavioral risk factors. Genetic
association studies have suggested low-penetrance alleles of extremely varied genes to be involved
in susceptibility to CRC in Caucasian populations.
Methods: Through a large genetic association study based on 1023 patients with sporadic CRC
and 1121 controls, we tested a panel of these low-penetrance alleles to find out whether they could
determine "genotypic profiles" at risk for CRC among individuals of the French population. We
examined 52 polymorphisms of 35 genes – drawn from inflammation, xenobiotic detoxification,
one-carbon, insulin signaling, and DNA repair pathways – for their possible contribution to
colorectal carcinogenesis. The risk of cancer associated with these polymorphisms was assessed by
calculation of odds ratios (OR) using multivariate analyses and logistic regression.
Results: Whereas all these polymorphisms had previously been found to be associated with CRC
risk, especially in Caucasian populations, we were able to replicate the association for only five of
them. Three SNPs were shown to increase CRC risk: PTGS1 c.639C>A (p.Gly213Gly), IL8 c.-
352T>A, and MTHFR c.1286A>C (p.Ala429Glu). On the contrary, two other SNPs, PLA2G2A
c.435+230C>T and PPARG c.1431C>T (p.His477His), were associated with a decrease in CRC risk.
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Further analyses highlighted genotypic combinations having a greater predisposing effect on CRC
(OR 1.97, 95%CI 1.31–2.97, p = 0.0009) than the allelic variants that were examined separately.
Conclusion: The identification of CRC-predisposing combinations, composed of alleles PTGS1
c.639A, PLA2G2A c.435+230C, PPARG c.1431C, IL8 c.-352A, and MTHFR c.1286C, highlights the
importance of inflammatory processes in susceptibility to sporadic CRC, as well as a possible
crosstalk between inflammation and one-carbon pathways.
Background
As in most Western countries, colorectal cancer (CRC) is a
major public health issue in France, where it is the second
most common cause of death from cancer among adults
[1]. Unfortunately, CRC diagnosis is often made at too
late a stage and this induces a dismal prognosis, empha-
sizing the need for prevention and early diagnostic tools
[2]. The development of such tools is, nonetheless, highly
dependent on the form of cancer being screened. Thus,
reliable genetic tests are already available to detect pheno-
typically well-characterized familial forms of CRC associ-
ated with high-penetrance alleles of genes, including APC
in familial adenomatous polyposis (FAP), DNA mismatch
repair genes in Lynch syndrome or hereditary non-poly-
posis colorectal cancer (HNPCC), and MUTYH in
MUTYH-associated polyposis (MAP) [3]. However, famil-
ial diseases together probably make up only a small per-
centage of all CRCs [2], and the development of
comparable screening tests appears more arduous and
remote for sporadic cases, which account for the large
majority of CRCs.
In contrast with their major role in familial CRCs, herita-
ble factors are not the only components of the etiology of
sporadic CRCs. Susceptibility to sporadic CRCs is multi-
factorial and derives from multiple interactive combina-
tions of numerous low-penetrance alleles and relevant
environmental or behavioral risk factors [2,4]. Independ-
ently, each low-penetrance allele contributes modestly to
the increase in CRC risk, but its interactions with other
susceptibility alleles and environmental factors can lead
to a substantial increase in CRC risk, especially when
exposed to certain dietary and lifestyle habits [4-6]. The
number of interactions is all the higher because the sus-
ceptibility genes can be involved in many different biolog-
ical pathways, which explains the extremely variable
phenotype encountered in sporadic CRCs.
Despite much criticism for their non-reproducibility and
weak statistical power [6], genetic association studies have
been widely used to decypher the mechanisms of cancer
susceptibility. Besides, their quality has improved greatly
over the past few years [7]. They recently started to pro-
duce very valuable results, as illustrated by the identifica-
tion of several susceptibility loci for colorectal cancers [8-
12]. Great expectations can now be held about the results
and positive consequences on medical oncology provided
by such studies. Beyond the search for susceptibility
genes, a global effort is currently being made in the field
of sporadic cancers, in order to determine which combi-
nations of genetic variants, i.e., which genetic back-
grounds, present at non rare frequencies in the general
population, are likely to confer an increase in cancer risk,
either alone, or by interacting with usual environmental
factors [4,5,13,14].
In order to be part of this effort, we have conducted a case-
controlled genetic association study based on a large
French population sample. This one already turned out to
be very useful by contributing to the finding of the new
CRC susceptibility locus at chromosome 8q24.21 made
by Zanke et al [9]. Yet, in the present study, our purpose
was somehow more modest as we did not attempt to iden-
tify new susceptibility loci or variants by a pangenomic
approach. Through an exploratory study, we tried to find
out whether combinations of variants already known for
their possible involvement in carcinogenesis – especially
in various Caucasian populations – could determine "gen-
otypic profiles" at risk for CRC among individuals of our
French study population. Thus, we focused on 52 allelic
variants of 35 candidate genes, selected through a review
of the literature on CRC susceptibility, and drawn from
five biological pathways relating to inflammation, xeno-
biotics detoxification, one-carbon, insulin signaling, and
DNA repair. Here, we report the results of our investiga-
tion on the risk for CRC associated with all 52 allelic var-
iants, analyzed singly or in combinations.
Methods
Experimental design and study population
From December 2002 to March 2006, two groups of 1023
patients (632 males and 391 females; mean ± SD age at
diagnosis 65.7 ± 10.1 years) and 1121 controls (609
males and 512 females; mean ± SD age at inclusion 61.9
± 10. years), all of Caucasian origin, were recruited within
the Pays de la Loire region of France.
Details of the study population characteristics have been
described elsewhere [15]. In short, all cases were patients
recruited in regional hospitals and clinics, with a personal
history of colorectal cancer diagnosed at an age of ≥ 40
years old. Any patient suspected of having a familial formBMC Cancer 2008, 8:326 http://www.biomedcentral.com/1471-2407/8/326
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of colorectal cancer (either Familial Adenomatous Poly-
posis, Hereditary Non Polyposis Colorectal Cancer or
MUTYH-Associated Polyposis) was excluded from the
study. Age- and sex-matched controls were recruited at
two regional Health Examination Centres; all were ≥ 40
years old and had no family history of colorectal cancer or
polyps. Two venous blood samples were collected from
each participant in an anonymous manner, after they had
legally provided a written informed consent. The study
was approved by both the local ethics committee CCPPRB
(Consultative Committee for the Protection of Person in
Biomedical Research) and by the national French ethics
committee CNIL (National Commission for Data protec-
tion and the Liberties). Each participant also answered the
same one-page standardized questionnaire pertaining to
life and food habit information. Endoscopy and histology
reports were obtained for each patient.
Selection of the low-penetrance genes and allelic variants
A review of the literature focused on susceptibility to spo-
radic colorectal cancer highlighted five biological path-
ways frequently cited for their role in colorectal
carcinogenesis: inflammation, one-carbon, signaling
insulin, xenobiotics detoxification, and DNA repair. In
these pathways, we selected 35 genes reported as known
or possible factors predisposing to CRC (ALOX5, ALOX12,
IL6,  IL8,  PLA2G2A,  PDL2,  PTGS1,  PTGS2,  PPARG,
CYP1A2,  CYP2E1,  CYP1B1,  CYP2C9,  EPHX1,  GSTA1,
GSTM1,  GSTM3,  GSTP1,  GSTT1,  NQO1,  SULT1A2,
UGT1A1, UGT1A6, GH1, IGF1, IGFBP3, IRS1, VDR, CBS,
MTHFD1,  MTHFR,  MTR,  MTRR,  TYMS,  OGG1), and
chose to investigate 52 polymorphisms -46 single nucle-
otide polymorphisms (SNPs) and 6 complex polymor-
phisms – in these 35 genes (Table 1). Among these 52
polymorphisms, 38 polymorphisms were exclusively
selected through our review of the literature, because of
their possible involvement in the predisposition to CRC
[16-30]; most of these polymorphisms reportedly modi-
fied the in vitro activity of the corresponding gene. It
should be noted that 6 of these polymorphisms – found
in CYP1A2, CYP2E1, CYP1B1 and CYP2C9-, which were
tested previously in our study population [15], are still
cited in the present study, given that they were included in
the combined analyses described below. The remaining
14 SNPs, located in the candidate genes PLA2G2A, PTGS1,
PTGS2, and PPARG, were first found by a dHPLC screen-
ing in two samples of 50 patients and 50 controls ran-
domly chosen within the whole study population. In fact,
we chose to select these 14 SNPs, because of their uneven
distribution between the two samples. With the exception
of the 4 SNPs in PLA2G2A, the other ten SNPs were also
found by our bibliographical survey on susceptibility to
CRC [5,17,31-34].
As regards the nomenclature that we used for the SNPs, we
referred to the databases dbNSP, SNPPER and SNP500
Cancer for the ID numbers, and we followed the Human
Variation Society (HGVS) mutation nomenclature for the
description of nucleotide and proteic sequence variants
[35]. Thereby, we corrected wrong notations abundantly
used in literature for some of the selected SNPs (e.g.,
PPARG C161T instead of c.1431C>T, or MTHFR A1298C
instead of c.1286A>C).
Genotype analysis
Every study participant was genotyped for the 52 poly-
morphisms selected. Genotypes were determined using
high-throughput TaqMan allelic discrimination tests for
the 46 SNPs, and fluorescent multiplex PCRs for the 6
complex polymorphisms [for details, see Additional files
1 and 2].
Statistical analysis
Single-SNP association study
All polymorphisms were tested for Hardy-Weinberg equi-
librium by a χ2 test in both patients and controls. An
appraisal was made on the association between allelic var-
iants and CRC risk, by calculation the odds ratio (OR) of
cancer cases together with 95 percent confidence intervals
(CI). Association tests consisted of comparing genotype
heterogeneity between the groups of patients and con-
trols. For each allelic variant, homozygotes for the major
allele were used as the reference group and compared to
the other two groups of heterozygotes and homozygotes
for the minor allele considered either separately (codom-
inant model), or gathered in a same group (dominant
model). We used logistic regression models for assessing
single SNP effects adjusted for gender and age covariates.
To estimate the risk for CRC, we first performed multivar-
iate analyses based on unconditional logistic regression,
adjusting for sex and age at date of reference (date of diag-
nosis for patients, and date of blood sample collection for
controls). To detect a potential overestimation of the odds
ratio by unconditional logistic regression, we then
employed conditional logistic regression on 811 age- and
sex-matched pairs of individuals (75.6% of the whole
study population, including 2*324 women, and 2*487
men). In each case, the significance of ORs was assessed
by calculation of p-values derived from likelihood-ratio
tests.
Multiple testing of 52 polymorphisms implies inevitably
a certain rate of false positive results. A correction is there-
fore required to lower as much as possible the rate of false
positives, even though the need to adjust multiple com-
parisons has been questioned by Rothman [36]. Yet, clas-
sical methods of correction such as Bonferroni's
adjustment are too drastic for genetic association studies
and lead to the rejection of many results, including trueB
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Table 1: Statistical analysis of association between CRC risk and polymorphisms selected for the study (n = 2144; OR calculations were adjusted according to age and sex).
Gene Name Nucleotidic change ** Proteic change ** SNP ID ** Ref *** Controls Cases +/- vs. +/+ -/- vs. +/+ +/- and -/- vs. +/+
+/+ +/- -/- +/+ +/- -/- OR 
(95%CI)
pO R  
(95% CI)
pO R  
(95% CI)
p
Inflammation ALOX5 c.760G>A p.Glu254Lys rs2228065 16 1121 0 0 1023 0 0 Rare Rare Rare
ALOX12 c.782G>A p.Gln261Arg rs1126667 16 361 549 211 357 498 168 0.93 
(0.76–1.12)
0.37 0.82 
(0.63–1.06)
0.09 0.90 
(0.75–1.08)
0.24
IL6 c.-239G>C rs1800795 17 435 504 182 363 489 171 1.12 
(0.92–1.35)
0.11 1.13 
(0.87–1.46)
0.35 1.12 
(0.94–1.34)
0.22
IL8 c.-352T>A rs4073 17 375 516 230 307 511 205 1.25 
(1.03–1.53)
0.02 1.12 
(0.88–1.44)
0.49 1.21 
(1.01–1.46)
0.04
PLA2G2A c.-859C>G rs11573156 d 738 337 46 627 349 47 1.20 
(1.00–1.45)
0.05 1.16 
(0.75–1.78)
0.39 1.20 
(1.00–1.43)
0.05
PLA2G2A c.132C>T p.Tyr44Tyr rs4744 d 742 333 46 635 342 46 1.17 
(0.97–1.42)
0.05 1.13 
(0.73–1.73)
0.47 1.17 
(0.98–1.40)
0.09
PLA2G2A c.185+88G>A rs2236772 d 1062 59 0 952 69 2 1.30 
(0.90–1.88)
0.14 Rare 1.35 
(0.94–1.94)
0.11
PLA2G2A c.435+230C>T rs11677 d 829 276 16 789 226 8 0.82 
(0.67–1.01)
0.07 0.50 
(0.21–1.19)
0.13 0.80 
(0.66–0.98)
0.03
PLD2 c.1731C>T p.Thr577Ile rs1052748 18 316 559 246 280 520 223 1.05 
(0.86–1.29)
0.63 1.00 
(0.78–1.27)
0.85 1.04 
(0.85–1.26)
0.82
PTGS1 c.22C>T p.Trp8Arg rs1236913 d,32,34 976 139 6 879 143 1 1.19 
(0.92–1.54)
0.30 0.18 
(0.02–1.54)
0.08 1.15 
(0.89–1.48)
0.29
PTGS1 c.50C>T p.Pro17Leu rs3842787 d,32,34 970 147 4 874 142 7 1.06 
(0.82–1.37)
0.58 2.17 
(0.62–7.61)
0.28 1.09 
(0.85–1.40)
0.51
PTGS1 c.639C>A p.Gly213Gly rs5788 d,32 858 243 20 747 254 22 1.24 
(1.01–1.53)
0.03 1.26 
(0.67–2.36)
0.45 1.24 
(1.02–1.52)
0.03
PTGS1 c.123G>A p.Gln41Gln rs3842788 d,32 1074 47 0 978 45 0 1.10 
(0.72–1.68)
0.81 Rare 1.10 
(0.72–1.68)
0.81
PTGS2 c.-646C>T rs20420 d,16 1121 0 0 1023 0 0 Rare Rare Rare
PTGS2 c.306G>C p.Val102Val rs5277 d,31 783 312 26 707 285 31 1.00 
(0.82–1.21)
0.90 1.25 
(0.73–2.16)
0.30 1.02 
(0.84–1.23)
0.85
PTGS2 c.1815+427T>C rs5275 d,31 494 499 128 433 476 114 1.08 
(0.90–1.30)
0.36 1.01 
(0.76–1.35)
0.91 1.07 
(0.90–1.27)
0.47
PTGS2 c.1815+1912A>G rs4648298 d,31 1062 59 0 959 64 0 1.31 
(0.90–1.89)
0.32 Rare 1.31 
(0.90–1.89)
0.32
PPARG c.36C>G p.Pro12Ala rs1801282 17 896 212 13 822 194 7 1.02 
(0.81–1.27)
0.98 0.47 
(0.19–1.20)
0.25 0.98 
(0.79–1.22)
0.85
PPARG c.1431C>T p.His477His rs3856806 33 875 217 29 803 211 9 1.07 
(0.86–1.33)
0.59 0.30 
(0.14–0.65)
0.003 0.97 
(0.79–1.20)
0.8
Xenobiotics CYP1A2 c.-163A>C rs762551 19–21 554 482 85 520 423 80 0.97 
(0.81–1.16)
0.46 1.08 
(0.77–1.51)
0.99 0.99 
(0.83–1.17)
0.87
detoxification CYP1A2 c.1548T>C p.Asn516Asn rs2470890 20,21 455 525 141 433 467 123 0.97 
(0.81–1.17)
0.47 0.97 
(0.73–1.28)
0.53 0.97 
(0.81–1.16)
0.94
CYP2E1 c.-1293G>C rs3813867 20 1032 88 1 954 67 2 0.81 
(0.58–1.13)
0.25 2.15 
(0.18–25.3)
0.52 0.82 
(0.59–1.15)
0.37
CYP2E1 c.-1053C>T rs2031920 20 1030 90 1 950 67 6 0.79 
(0.57–1.11)
0.20 5.74 
(0.67–49.2)
0.09 0.85 
(0.61–1.18)
0.33
CYP1B1 c.1294C>G p.Leu432Val rs1056836 19–21 370 577 174 322 510 191 0.98 
(0.81–1.20)
0.87 1.22 
(0.94–1.58)
0.07 1.04 
(0.86–1.25)
0.68
CYP2C9 c.430C>T p.Arg144Cys rs1799853 19–21 823 281 17 751 251 21 0.96 
(0.79–1.18)
0.83 1.34 
(0.69–2.59)
0.36 0.98 
(0.81–1.20)
0.88
EPHX1 c.337T>C p.Tyr113His rs1051740 19–21 564 469 88 525 409 89 0.92 
(0.77–1.11)
0.47 1.12 
(0.81–1.54)
0.61 0.95 
(0.80–1.13)
0.58
GSTA1 c.-4605G>A rs3957356 22 372 549 200 333 517 173 1.07 
(0.88–1.30)
0.60 1.03 
(0.79–1.33)
0.79 1.06 
(0.88–1.28)
0.53B
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GSTM1 null 19–21 161 392 568 174 305 544 0.72 
(0.55–0.94)
0.01 0.86 
(0.67–1.10)
0.33 0.80 
(0.63–1.02)
0.07
GSTM3 c.468+21delAGG 19,20 788 308 25 679 316 27 1.19 
(0.98–1.44)
0.07 1.09 
(0.62–1.92)
0.42 1.18 
(0.98–1.42)
0.08
GSTP1 c.313A>G p.Ile105Val rs1695 19–21 511 486 124 465 447 111 1.04 
(0.86–1.24)
0.90 0.96 
(0.72–1.29)
0.91 1.02 
(0.86–1.21)
0.82
GSTP1 c.341C>T p.Ala114Val rs1138272 19–21 966 146 9 882 137 4 1.00 
(0.77–1.29)
0.83 0.44 
(0.13–1.47)
0.22 0.96 
(0.75–1.24)
0.78
GSTT1 null 19–21 433 483 205 411 429 183 0.95 
(0.78–1.15)
0.49 0.97 
(0.75–1.23)
0.62 0.95 
(0.80–1.14)
0.58
NQO1 c.415C>T p.Arg139Trp rs4986998 20,21 1056 65 0 961 62 0 1.06 
(0.74–1.54)
0.80 Rare 1.06 
(0.74–1.54)
0.80
NQO1 c.559C>T p.Pro187Ser rs1800566 19,21 719 351 51 633 343 47 1.09 
(0.91–1.32)
0.26 1.08 
(0.71–1.64)
0.83 1.09 
(0.91–1.31)
0.34
SULT1A2 c.714A>C p.Asn235Thr rs1059491 21 535 458 128 481 437 105 1.09 
(0.90–1.31)
0.52 0.92 
(0.69–1.23)
0.53 1.05 
(0.88–1.25)
0.58
UGT1A1 c.-3279T>G rs4124874 23 359 546 216 308 515 200 1.09 
(0.90–1.33)
0.34 1.08 
(0.84–1.39)
0.54 1.09 
(0.90–1.31)
0.37
UGT1A1 c.-3156G>A rs10929302 23 535 495 91 474 458 91 1.03 
(0.86–1.24)
0.65 1.11 
(0.80–1.53)
0.45 1.04 
(0.88–1.24)
0.63
UGT1A6 c.541A>G p.Thr181Ala rs2070959 22 508 504 109 470 443 110 0.94 
(0.78–1.13)
0.97 1.07 
(0.80–1.45)
0.56 0.96 
(0.81–1.15)
0.67
UGT1A6 c.552A>C p.Arg184Ser rs1105879 22 460 529 132 438 454 131 0.89 
(0.74–1.07)
0.26 1.03 
(0.77–1.36)
0.77 0.92 
(0.77–1.09)
0.34
Insulin GH1 c.456+90T>A rs2665802 24 326 561 234 316 527 180 0.96 
(0.79–1.17)
0.75 0.80 
(0.62–1.03)
0.07 0.91 
(0.76–1.10)
0.36
IGF1 c.-1006CA(19) 25 764 152 205 689 159 175 1.12 
(0.87–1.44)
0.24 0.95 
(0.75–1.20)
0.63 1.02 
(0.85–1.23)
0.81
IGFBP3 c.-336A>C rs2854744 25 287 571 263 259 502 262 0.99 
(0.80–1.22)
0.80 1.13 
(0.88–1.44)
0.42 1.03 
(0.85–1.26)
0.76
IRS1 c.2911G>A p.Gly971Arg rs1801278 25 956 158 7 865 152 6 1.01 
(0.79–1.29)
0.62 0.86 
(0.28–2.66)
0.92 1.00 
(0.79–1.28)
0.97
VDR c.1024+283G>A rs1544410 25 423 520 178 372 493 158 1.11 
(0.92–1.35)
0.43 1.06 
(0.81–1.37)
0.94 1.10 
(0.92–1.31)
0.31
One-carbon CBS c.844ins68 26,27 928 185 8 829 185 8 1.12 
(0.89–1.41)
0.32 1.20 
(0.44–3.28)
0.82 1.12 
(0.90–1.41)
0.31
MTHFD1 c.1958G>A p.Arg653Gln rs2236225 28 339 557 225 322 494 207 0.91 
(0.75–1.12)
0.49 0.99 
(0.77–1.27)
0.80 0.94 
(0.78–1.13)
0.48
MTHFR c.665C>T p.Ala222Val rs1801133 26,27 457 515 149 435 452 136 0.93 
(0.77–1.12)
0.38 0.95 
(0.73–1.25)
0.76 0.93 
(0.78–1.11)
0.44
MTHFR c.1286A>C p.Ala429Glu rs1801131 26,27 577 443 101 484 432 107 1.20 
(1.00–1.45)
0.04 1.26 
(0.93–1.70)
0.12 1.21 
(1.02–1.44)
0.03
MTR c.2756A>G p.Asp919Gly rs1805087 26,27 742 335 44 706 289 28 0.90 
(0.74–1.09)
0.31 0.64 
(0.39–1.06)
0.10 0.87 
(0.72–1.05)
0.14
MTRR c.66A>G p.Ile22Met rs1801394 26,27 322 568 231 291 515 217 1.01 
(0.83–1.24)
0.97 1.01 
(0.79–1.30)
0.75 1.01 
(0.84–1.23)
0.89
TYMS c.943+447del TTAAAG 27 524 482 115 456 456 110 1.13 
(0.94–1.36)
0.36 1.04 
(0.77–1.39)
0.52 1.11 
(0.94–1.33)
0.22
DNA repair* OGG1 c.977C>G p.Cys326Ser rs1052133 29 668 402 51 651 321 51 0.84 
(0.69–1.01)
0.05 1.04 
(0.69–1.57)
0.90 0.86 
(0.72–1.03)
0.09
* SNP OGG1 c.977C>G was chosen to be analyzed together with 6 monoallelic germline mutations of the MUTYH gene – also belonging to the base excision repair system like OGG1 – which 
were studied previously for their predisposing effect on sporadic CRC (Küry et al., Genet Test; ref [30]).
** Nomenclature referring to the databases dbNSP, SNPPER and SNP500Cancer.
*** Ref: numbers correspond to bibliographical references, and the "d" mark corresponds to SNPs identified by dHPLC screening in 50 patients with CRC and 50 controls from the study 
population.
Table 1: Statistical analysis of association between CRC risk and polymorphisms selected for the study (n = 2144; OR calculations were adjusted according to age and sex). BMC Cancer 2008, 8:326 http://www.biomedcentral.com/1471-2407/8/326
Page 6 of 14
(page number not for citation purposes)
associations. We therefore followed the approach pro-
posed by Storey et al., and we estimated the false discovery
rate (FDR), more appropriate in large sets of hypotheses
than multiple testing procedures [37]. For this estimation,
we calculated the q-value, setting the threshold at 0.05.
We considered findings that met a false discovery rate
(FDR) criterion of 20% to be robust.
Multiple-SNP association study
Modeling strategy for analysis of genotypic combinations
According to the results of single polymorphisms analy-
ses, we tested all possible combinations of N polymor-
phisms composed by the N allelic variants found to be
significantly associated with CRC risk, and by polymor-
phisms associated with marginally or non-significant ORs
having a p value comprised between 0.05 and 0.25. As a
comparison, we also analyzed a hundred of combinations
of N polymorphisms randomly selected from any of the
52 ones included in our study. For each polymorphism,
the genotype was coded 0 if the rare variant was absent, 1
if present at heterozygous state, 2 if present at
homozygous state. Because most of the homozygotes for
the minor allele of the polymorphisms tested were often
extremely rare, we assumed in our model that the rare
effect allele was dominant. In other terms, if a polymor-
phism predisposed to CRC, genotypes 1 and 2 were con-
sidered predisposing to CRC; on the contrary, genotypes 1
and 2 were considered protective if the effect of the minor
variant of the polymorphism was rather protective. For
each polymorphism included in a combination, we there-
fore tested two hypotheses: 1. either we considered that
the minor allele was predisposing to CRC and therefore
the CRC-predisposing genotypes were 1 and 2, whereas
genotype 0 was considered protective; 2. or we considered
that the minor allele was associated with a decreased CRC
risk, and therefore 0 was considered to be the predispos-
ing genotype, whereas genotypes 1 and 2 were considered
protective. Thus, for every combination of N SNPs tested,
we also tested every possible combination of x protective
and N-x predisposing minor alleles (with x ranging from
0 to N), each combination tested representing a different
model.
For each test of a combination or model, we compared
three groups. The first group was composed by individuals
exhibiting genotype 0 for the N SNPs, i.e., carrying the fre-
quent allele at homozygous state for the N SNPs; this
group, theoretically the most frequent group in the study
cohort, was set as a reference, and the relating combina-
tion of genotypes was considered as the "reference pat-
tern" exhibiting a null or very weak effect on CRC risk. The
second group was composed of individuals exhibiting
patterns of genotypic combinations composed of N pre-
disposing genotypes (predisposing patterns). The third
group comprised the individuals exhibiting all other pos-
sible combinations of genotypes (mixed patterns).
In the same way as for single SNP association study, het-
erogeneity between the groups of patients and controls
was translated into colorectal cancer risk associated with
genotypic patterns, assessed by OR calculation together
with 95 percent confidence intervals. We first used uncon-
ditional logistic regression, adjusting for sex and age, and
we compared the results observed to those obtained by
conditional logistic regression analysis restricted to 811
age- and sex-matched pairs of individuals. We eventually
assessed the robustness of the associations observed by
applying the false discovery rate (FDR) method, setting
the threshold at 0.05.
Validation of the logistic regression model
In order to validate the logistic regression model, we
applied a standard Monte Carlo bootstrap (random resa-
mpling with replacement from the original dataset) pro-
cedure based on 1000 replicates. We calculated the 5th and
95th percentiles from the resulting distributions to deter-
mine the lower and upper limits of the confidence inter-
val.
Alternatively, we examined the internal consistency of the
results obtained for the model. Analyses of genotypic
combinations were replicated on stratifications of the
study population determined according to age, geograph-
ical origin, random selection, or inference of population
structure [Additional file 1].
Results
The allele frequencies we found for each of the 52 poly-
morphisms tested were consistent with those reported in
literature and in dbSNP http://www.ncbi.nlm.nih.gov/
projects/SNP/ for Caucasian populations. Two of the 52
polymorphisms analyzed turned out to be monomorphic.
The 50 others were all at Hardy-Weinberg equilibrium.
Results of the unconditional logistic regression analyses
for CRC association with polymorphisms considered
independently are described in Table 1. Alternative results
of conditional logistic regression restricted to 811 age-
and sex-matched pairs of individuals are reported in Addi-
tional file 3.
Six associations between CRC risk and allelic variants
were determined by both unconditional and conditional
logistic regression analyses. For SNPs PTGS1  c.639C>A
(p.Gly213Gly), IL8 c.-352T>A, and MTHFR  c.1286A>C
(p.Ala429Glu), minor alleles appeared associated with an
increase in CRC, whereas for SNPs PLA2G2A
c.435+230C>T,  PPARG  c.1431C>T (p.His477His), they
were associated with a decrease in CRC risk. Application
of the false discovery rate to the results obtained byBMC Cancer 2008, 8:326 http://www.biomedcentral.com/1471-2407/8/326
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unconditional logistic regression analysis showed a value
of about 0.5 for these five findings, suggesting that the
associations were not very robust. Yet, on the contrary, q-
values determined from conditional logistic regression
analysis were found between 0.07 and 0.26 for the same
findings, rather suggesting quite robust associations
[Additional file 3]. Our analyses also showed a protective
effect of the variant GSTM1  null carried at the hetero-
zygous state on CRC risk. However, this observation is not
relevant at the biological level since the loss of activity of
the GSTM1 enzyme, or GSTM1 deficiency, is associated
with a deletion carried on both alleles. In fact, comple-
mentary analyses in our study population revealed that
individuals carrying two deleted alleles did not have a sig-
nificantly different risk of CRC compared to carriers of
one or zero deleted alleles (OR 1.08, 95% CI 0.91–1.21, p
= 0.4), which is consistent with two meta-analyses per-
formed on this polymorphism [19,38]. Therefore, the
CRC-predisposing effect observed for GSTM1 null allele is
to consider with great caution, all the more because the q-
value of 0.4 calculated for this finding would rather sug-
gest a false positive result. Two additional CRC-predispos-
ing effects were observed for SNPs PLA2G2A c.-859C>G
and CYP1B1 c.1294C>G by conditional logistic regression
analysis [Additional file 3], but were not found when
using unconditional method applied to the whole study
population; they were therefore considered as false posi-
tives.
Since five SNPs were undoubtfully found associated with
a modification of CRC risk in single-SNP analyses, we
focused our further analyses on combinations of five
allelic variants, as described in Methods. Among all the
genotypic combinations tested, only one showed a statis-
tically significant association with an increased risk of
CRC, which appeared robust according to the calculation
of FDR (q-value < 0.1). This combination was composed
by the very same five SNPs that had been found independ-
ently associated with CRC risk from single-SNP analyses.
Additional file 4 uses the example of this precise set of five
SNPs to illustrate the different models of genotypic com-
binations tested for every set of five polymorphisms –
picked from the 52 polymorphisms of the study – which
we tested. The most predisposing patterns for this combi-
nation, presented in Table 2, combine genotypes 1 and 2
for  PTGS1  c.639C>A,  IL8  c.-352T>A, and MTHFR
c.1286A>C, and 0 for PLA2G2A  c.435+230C>T and
PPARG c.1431C>T. These predisposing patterns appeared
to be associated with a highly significant increase in color-
ectal cancer, either compared to the reference pattern
alone (OR 2.65; 95% CI 1.58–4.42 with p = 0.0005), or
compared to reference and mixed patterns gathered (OR
1.97; 95% CI 1.31–2.97 with p = 0.0009).
Validation of the model by bootstrapping and examina-
tion of internal consistency strengthened the above
results. By bootstrapping, we calculated a mean ± SD OR
of 1.86 ± 0.41 (95%CI 1.23–2.85, p = 0.003). Examina-
tion of internal consistency confirmed a trend in an
increased CRC risk associated with the predisposing com-
bination patterns, regardless of the mode of stratification
used [Additional file 5]. No effect of gender or anatomical
sub-location was noted. Most of the associations observed
were statistically significant, but certain stratifications
determined according to geographical origin and/or age
displayed a greater effect regarding the predisposing com-
bination patterns (Table 3). Among the 2144 individuals
composing the whole study population, the strongest
association was found in individuals of ≤ 67 years of age
and originating from the French département  of the
Vendée.
Discussion
In this study, we have used a candidate gene approach to
examine the associations between colorectal cancer risk
and 52 allelic variants distributed in 35 genes drawn from
pathways of inflammation, metabolism of xenobiotics
detoxification, one-carbon, insulin signaling, and DNA
repair. To our knowledge, we are describing here within
one of the most comprehensive investigations on popula-
tions of this kind, covering more than 1000 patients with
sporadic colorectal cancer, and 1000 controls, i.e., in the
range of 500–2000 case-control pairs defined by Brennan
to detect the statistically significant effect of polymor-
phisms [39]. Obviously, the list of polymorphisms which
we designed here is non-comprehensive, and it must be
seen as a panel test, a first attempt in the search for CRC-
predisposing "genetic profiles".
With the exception of the 4 SNPs in PLA2G2A that we had
selected by dHPLC, all the allelic variants chosen for the
present study had previously been found to be associated
with a modification of CRC risk in at least one study.
However, we have been able to replicate the association
with CRC risk for only 5 of the 52 polymorphisms tested
(Table 1). By independent single-SNP analyses, three
SNPs were shown to increase CRC risk: PTGS1 c.639C>A,
IL8 c.-352T>A, and MTHFR c.1286A>C. Two other SNPs,
PLA2G2A c.435+230C>T and PPARG c.1431C>T, were on
the contrary associated with a decrease in CRC risk. Com-
binations of the CRC-predisposing alleles relating to these
five variants determine "genotypic profiles" at signifi-
cantly higher risk of CRC (OR 1.97, 95% CI 1.31–2.97).
Among the individuals exhibiting these profiles, younger
individuals (≤ 67 years) from the Vendée seem to be even
more predisposed to CRC (OR 6.36, 95% CI 1.44–28.09).
However, the size of the population sample analyzed here
is too small to draw definitive conclusions on any age- or
geographical-effect. In the same way, the consistency ofBMC Cancer 2008, 8:326 http://www.biomedcentral.com/1471-2407/8/326
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the risk profile was lost in some of the study population
subgroups used for the analyses reported in Additional
file 5.b, certainly because of their relatively small size.
Caution is therefore required, when considering the true
significance of this risk profile, even though bootstrap-
ping results tend to show its robustness [Additional file
5.a]. It is noteworthy that a sixth polymorphism, GSTM1
null allele, showed a protective effect in independent
analyses of allelic variants, but the significance of its asso-
ciation with CRC risk remained dubious, and was not
confirmed by multiple-SNP analyses, contrary to the five
other polymorphisms.
To investigate further the CRC-predisposing combina-
tions that emerged from our analyses, we tested their pos-
sible interactions with the environmental and lifestyle risk
factors reported in our study questionnaire (physical
activity, cooking methods, and consumption of alcohol,
tobacco, red meat, cold cuts, white meat and poultry
bread, dairy products, fish, fruits, pastries, or vegetables),
by use of SNPStats [40]. Indeed, in the same study popu-
lation, we had previously observed an interaction
between allelic combinations of CYP genes and consump-
tion of red meat which leads to a strong increase in CRC
risk [15]. In the present study, we did not observe any
comparable gene-environment interaction that could
remain statistically significant throughout multiple
adjustment and/or test for internal consistency in patient
and control sub-groups (data not shown). Given that four
of the SNPs composing the CRC-predisposing combina-
tions are related to inflammation, the most relevant "envi-
ronmental" factor to be tested here would have actually
been NSAIDs treatment. But, since this item did not figure
in our questionnaire on life-habits [15] – we assumed that
it would have introduced a bias in the design of the con-
trol group-, we were unfortunately unable to analyze its
interaction with the CRC-predisposing genotypic combi-
nations of the five SNPs mentioned above.
The respective biological impact of the five variants PTGS1
c.639C>A, IL8 c.-352T>A, MTHFR c.1286A>C, PLA2G2A
c.435+230C>T, and PPARG  c.1431C>T provide some
Table 2: Analysis of association between combinations of genotypes and risk for colorectal cancer, in the entire study population.
A. Encoding of theoretical combinations of genotypes
Patterns of genotypic combinations Effect on colorectal 
cancer
PTGS1 c.639C>A PLA2G2A 
c.435+230C>T
PPARG c.1431C>T IL8 c.-352T>A MTHFR c.1286A>C
0 0 0 0 0 Null or very weak 
(reference pattern)
0 1 or 2 1 or 2 0 0 Protective (protective 
patterns) *
1 or 2 0 0 1 or 2 1 or 2 Predisposing 
(predisposing patterns)
Other genotypes Average 
(mixed patterns)
B. Analysis of observed combination of genotypes association with colorectal cancer (n = 2144, adjusted by sex and age)
Patterns of 
genotypic 
combinations
Controls Patients OR (95% CI) P-value**
Reference pattern 95 (8.5%) 63 (6.2%) 1.00
Protective patterns 7 (0.6%) 4 (0.4%) 0.86 (0.24–3.06) 0.8180
Mixed patterns 978 (87.2%) 890 (87.0%) 1.37 (0.98–1.90) 0.0602
Predisposing patterns 41 (3.7%) 66 (6.4%) 2.65 (1.58–4.42) 0.0005
Reference and mixed 
patterns
1080 (96.3%) 957 (93.5%) 1.00
Predisposing patterns 41 (3.7%) 66 (6.5%) 1.97 (1.31–2.97) 0.0009
* These patterns were inferred from the identification of the predisposing patterns.
** Observed associations in bold met a false discovery rate criterion of < 0.1.B
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Table 3: Replications of genotypic combinations analyses on stratifications of the patients and controls groups determined according to geographical origin and/or age. 
Individuals originating from Vendée Individuals ≤ 67 years Individuals from Vendée ≤ 67 years
Genotypic combinations patterns Controls 
(n = 189)
Cases 
(n = 420)
OR 
(95% CI)
p* Controls 
(n = 768)
Cases 
(n = 529)
OR 
(95% CI)
p* Controls 
(n = 134)
Cases 
(n = 232)
OR 
(95% CI)
p*
R e f e r e n c e  p a t t e r n 1 42 9 1 . 0 0 6 53 11 . 0 0 1 21 6 1 . 0 0
Mixed patterns 171 359 0.92 
(0.47–1.83)
676 460 1.42 
(0.91–2.21)
120 195 1.15 
(0.52–2.56)
Predisposing patterns 4 32 3.80 
(1.10–13.19)
0.011 27 38 3.00 
(1.56–5.77)
0.003 22 17.22 
(1.38–37.80)
0.009
Reference and mixed patterns 185 388 1.00 741 491 1.00 132 211 1.00
Predisposing patterns 4 32 4.14 
(1.42–12.08)
0.002 27 38 2.17 
(1.31–3.61)
0.003 22 16.36 
(1.44–28.09)
0.002
OR calculations were all adjusted by age and sex.BMC Cancer 2008, 8:326 http://www.biomedcentral.com/1471-2407/8/326
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clues to the predisposition to CRC associated with some
of the genetic combinations that they compose. Thus,
PLA2G2A c.435+230C>T and PTGS1 c.639C>A, belong to
genes which encode proteins following each other in the
enzymatic cascade of the arachidonic acid pathway.
PLA2G2A catalyzes the hydrolysis of membrane phoso-
pholipids, thereby releasing unsaturated fatty acids,
including arachidonic acid [41]. The latter becomes the
substrate of PTGS1, which in turn catalyzes the formation
of prostaglandin H2 (PGH2), a precursor for a number of
inflammatory molecules – eicosanoids – that promote
colorectal carcinogenesis [42]. Until now, out of the
potential key players in the CRC process, more attention
has been given to another element of the arachidonic acid
pathway,  PTGS2, rather than to PTGS1  or  PLA2G2A
[31,43]. The interest for PTGS2 in CRC risk stems from its
expression induced by pathophysiological conditions
such as tumorigenesis or inflammatory situations [16].
However, we found no significant modification of CRC
risk associated with any of the four PTGS2 SNPs we tested
(Table 1). In contrast, PTGS1 is constitutively expressed
and its implication in CRC risk has not been investigated
very much, since its carcinogenetic role through induction
of PTGS2 has been suggested only recently [16,34]. Thus,
to our knowledge, the synonymous polymorphism
c.639C>A (p.Gly213Gly) that we found as having a pre-
disposing effect on CRC (OR 1.24) at the heterozygous
(CA) or homozygous state (AA), had not been examined
within this context to date and its precise impact on
PTGS1 activity would require further functional studies.
In the same way, the four PLA2G2A SNPs we studied have
not yet been tested within the CRC risk context. Therefore,
there is no possible point of comparison for the protective
effect relating to CRC that we found for the allele
c.435+230T carried at homozygous state (OR 0.80,
95%CI 0.66–0.98). Because of its localization within the
Mom-1 (Min modifier) locus, and its promotion of
tumors in APCMin mice, it had first been suggested that
PLA2G2A  may represent a tumor suppressor gene
involved in familial forms of CRC [44]. As a result, such a
role of PLA2G2A in FAP genesis had been ruled out in
humans [41,45]. However, the contribution of PLA2G2A
to sporadic CRC predisposition cannot be excluded, and
it has been suggested that the increase in PLA2G2A expres-
sion could cause the accumulation of arachidonic acid, a
molecule likely to have pro-apoptotic properties [41]. A
hypothesis for the protective role of variant c.435+230T
might therefore be its enhancement of PLA2G2A expres-
sion.
PPARG c.1431C>T (aka C161T) and IL8 c.-352T>A, also
relate to inflammation or immune response. PPARγ (per-
oxisome proliferator-activated receptor gamma) is a
nuclear receptor tightly linked to the arachidonic acid
pathway, in that it is activated by various eicosanoids [46].
Essential to adipocyte differentiation and to regulation of
lipid metabolism, PPARγ is thought to have overall tumor
suppressive properties, exerted notably in CRC [46-48]. A
protective effect on CRC risk had been reported for the
rare allele of variant PPARG  c.36C>G (p.Pro12Ala)
[49,50], but we were not able to reproduce this observa-
tion in our study population, perhaps because the refer-
ence studies were designed on smaller populations –
about 200 case-control pairs-. On the other hand, we
noted a significantly decreased risk of CRC associated
with the rare allele of variant c.1431C>T (p.His477His) at
the homozygous state (OR 0.30, 95%CI 0.14–0.65).
These results are consistent with those reported in an ear-
lier study on colorectal adenoma [48], but they are incon-
sistent with the contrary observations made by another
team investigating CRC [33]. Given the controversial
effect assigned to PPARG  c.1431C>T, functional assays
would be required to understand the exact role of this lit-
tle-investigated polymorphism.
As regards IL8, it encodes a pro-inflammatory chemokine,
released by infiltrating lymphocytes, in response to expo-
sure of the colonic epithelium to toxic and pathologic
challenges [50]. The allelic variant IL8 c.-352T>A has been
found to be associated with CRC risk, even though the
effect attributed to rare allele A goes from null [51], to pre-
disposing or even protective [17,52]. As regards our study,
we found that genotypes c.352AA or c.352TA were associ-
ated with an elevated risk of CRC compared to genotype
c.352TT (OR 1.21, 95%CI 1.01–1.46). The debate on the
true carcinogenetic role of variant c.-352T>A probably
comes from its controversial impact on IL8 transcription,
sometimes described as an enhancement [51], sometimes
as a downregulation [52]. As IL8 contributes to chronic
inflammation, it would make sense that its overexpres-
sion would increase the risk for CRC, and therefore the
allele c.-352A may rather enhance the transcriptional
activity of the gene.
The fifth gene highlighted by our analyses, MTHFR (5,10-
methylenetetrahydrofolate reductase), is part of the one-car-
bon metabolic pathway, involved in both DNA methylation
and DNA synthesis. The MTHFR enzyme synthesizes 5-meth-
yltetrahydrofolate, the primary circulatory form of folate,
which represents a fundamental methyl donor in cellular
metabolism [26]. The influence of MTHFR activity on folate
status could be important in CRC neoplasia, since folate defi-
ciency could cause DNA hypomethylation, and/or induce
uracil misincorporation during DNA synthesis, which would
lead to mutations and chromosomal damage [26,27,53].
Two polymorphisms c.665C>T (also reported as C677T) and
c.1286A>C (aka c.1298A>C), have been widely tested for
modification of CRC risk, because of the reduction in
MTHFR activity induced by their minor allele. In the present
study, we found no effect for c.665C>T, whereas we observedBMC Cancer 2008, 8:326 http://www.biomedcentral.com/1471-2407/8/326
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an elevated risk of CRC associated with genotypes c.1286CC
or c.1286AC compared to genotype c.1286AA (OR 1.21,
95%CI 1.02–1.44). At first sight, these results appear difficult
to compare with the greatly inconsistent or even conflicting
earlier results, and reviewed in two recent comprehensive
meta-analyses [54,55]. However, this discrepancy in the
overall results could be explained by the variation of the pol-
ymorphisms effect according to folate status. Mu et al. sug-
gested indeed that genotypes reducing MTHFR activity – here
c.1286CC or c.1286AC – would favor cancer risk when die-
tary folate levels are low, by inducing a DNA hypomethyla-
tion causing DNA damage and mutations [56]. When folate
levels are adequate, the reduced MTHFR activity induced by
the same genotypes would lead to a great pool of methylene-
tetrahydrofolate available for DNA synthesis, and therefore
prevent cancer by diminishing uracil misincorporation.
Moreover, it has been suggested that, according to its admin-
istration prior or further to the existence of preneoplastic
lesions, folate would rather prevent or increase tumor devel-
opment, respectively [53].
All these biological data considered, our work underlines
the important contribution of inflammatory processes to
CRC susceptibility in our study population, and it points
to a possible crosstalk between inflammation and one-
carbon pathways. The four allelic variants of genes PTGS1,
PLA2G2A,  PPARG, and IL8  might favor inflammatory
processes, whereas the MTHFR  allelic variant could
induce a DNA hypomethylation altering the expression of
the putative tumor suppressor gene PPARG. Two recent
studies on diabetes and cardiovascular diseases have sug-
gested a common pathobiological mechanism between
the inflammation process and genotype TT of MTHFR
c.665C>T (aka C677T), i.e., a genotype inducing a lower
MTHFR activity like genotype MTHFR c.1286CC [57,58].
However, our results do not enable to conclude to an
interaction between the five allelic variants. Indeed, the
odd ratios associated with the observed CRC-predisposing
combinations are certainly not strong enough, and our
method is not the most appropriate one for an investiga-
tion on gene-gene interactions.
Conclusion
Combinations of alleles PTGS1  c.639A,  PLA2G2A
c.435+230C, PPARG c.1431C, IL8 c.-352A, and MTHFR
c.1286C determine "genotypic profiles" at significantly
higher risk of CRC (OR 1.97, 95% CI 1.31–2.97), in a
small percentage of the French population. The identifica-
tion of these CRC-predisposing combinations highlights
the importance of inflammatory processes in susceptibil-
ity to sporadic CRC, as well as a possible crosstalk
between inflammation and one-carbon pathways.
To find their significance, our results would obviously
need to be reproduced. Indeed, replication represents a
key step for establishing the credibility of any genotype-
phenotype association [59]. Only a validation in other
Caucasian populations would therefore enable to con-
sider the five above variants and their related genotypic
combinations as relevant risk markers for sporadic CRC.
Moreover, even though the size of our population sample
is quite large, it is not large enough to draw definitive con-
clusions on the statistical significance of the polymor-
phisms-disease associations observed. In order to reach
such conclusions, our results should be combined to a
meta-analysis, since this tool is particularly robust to esti-
mate population-wide effect of genetic risk factors in dis-
eases [60]. In any case, our observations would warrant
investigations on possible interactions between NSAIDs
and combinations of polymorphisms from the five genes
we have highlighted here, which our questionnaire unfor-
tunately did not enable us to achieve. The results of our
study also call for more comprehensive investigations into
polymorphisms of inflammation genes – especially those
belonging to the arachidonic acid pathway-, as candidate
risk factors for CRC. In fact, the CRC-predisposing combi-
nations we identified account for only 5% of our study
population, which means that many more predisposing
combinations, involving different and maybe common
polymorphisms, are still to be found. Very large genetic
association studies on candidate genes of inflammation
may make it possible to find the most frequent predispos-
ing combinations, and thus make the first step towards
drawing up recommendations for clinical practice guide-
lines regarding sporadic CRC.
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